CIMERLI® (ranibizumab-eqrn) Sales Exceed 100,000 Doses in First Year of Launch
04. Oktober 2023 08:30 ET
|
Coherus BioSciences, Inc.
– CIMERLI® is the #1 ranibizumab biosimilar with 25% ranibizumab market share* – – Demonstrated safety and efficacy in clinical trials and real-world settings – – Robust and reliable supply...
Coherus Applauds Congressional Designation of September 30th as Rare Cancer Day
02. Oktober 2023 09:00 ET
|
Coherus BioSciences, Inc.
- Bipartisan resolution highlights the challenges patients with rare cancers face and raises awareness and supports efforts to improve early diagnosis and development of effective treatments - - Many...
Coherus Announces Three Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
27. September 2023 09:10 ET
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today announced the presentation of three abstracts from its innovative immuno-oncology...
FDA Issues Complete Response Letter (CRL) for UDENYCA® ONBODY™ Biologics License Application Solely Due to an Ongoing Review of Inspection Findings at a Third-Party Filler; Coherus Also Announces Completion of Toripalimab FDA Inspections
25. September 2023 08:30 ET
|
Coherus BioSciences, Inc.
– No issues with clinical efficacy or safety, trial design, labeling, drug substance manufacturing, or device design or manufacturing were identified in the UDENYCA® ONBODY™ CRL – – No additional...
Coherus BioSciences Announces New Employment Inducement Grants
22. September 2023 21:00 ET
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., Sept. 22, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective September 20, 2023, the compensation...
Coherus Completes Surface Oncology Acquisition
08. September 2023 09:05 ET
|
Coherus BioSciences, Inc.
– Clinical-stage product candidates, casdozokitug and CHS-114, significantly advancenext-generation immuno-oncology portfolio focused on the tumor microenvironment – – I-O combinations will...
Coherus BioSciences to Participate at Upcoming September Investor Conferences
01. September 2023 16:01 ET
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., Sept. 01, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced that senior management will participate in the following investor...
Coherus BioSciences Announces New Employment Inducement Grants
22. August 2023 17:35 ET
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., Aug. 22, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective August 20, 2023, the compensation...
Coherus BioSciences Reports Second Quarter 2023 Financial Results and Business Highlights
02. August 2023 16:01 ET
|
Coherus BioSciences, Inc.
– Net revenue rose 81% from prior quarter to $58.7 million –– CIMERLI® net sales quadrupled to $26.7 million compared to prior quarter –– UDENYCA® autoinjector launched in late May, and YUSIMRY™...
Coherus BioSciences to Report Second Quarter 2023 Financial Results on August 02, 2023
26. Juli 2023 16:05 ET
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., July 26, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced its second quarter 2023 financial results will be released after market...